Philip Morris Rebuts 'Cynical' Claims About £1bn Vectura Buy

Tobacco Giant Moving Into Pharma

Buying the UK inhalation specialist Vectura will be key to the transformation of Philip Morris International as it looks to reduce its reliance on smoking products, CEO Jacek Olczak has declared.

Cigs
PMI looks to drugs to reduce its reliance on cigarettes • Source: Alamy

It may seem ironic to many that a tobacco company is buying a respiratory specialist biotech but Philip Morris International (PMI) is not expecting any backlash for its planned £1.04bn ($1.44bn) acquisition of the UK's Vectura Group plc, insisting that the purchase is a key component of a shift from selling cigarettes to becoming "a broader healthcare and wellness company."

Eyebrows were raised when it was announced on 9 July that PMI had outbid private equity group Carlyle to get...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Respiratory

More from Therapeutic Category